Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors

PURPOSE: Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Trahair, Toby, Gifford, Andrew J., Fordham, Ashleigh, Mayoh, Chelsea, Fadia, Mitali, Lukeis, Robyn, Wood, Andrew C., Valvi, Santosh, Walker, Roderick D., Blackburn, James, Heyer, Erin E., Mercer, Tim R., Barbaric, Draga, Marshall, Glenn M., MacKenzie, Karen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446396/
https://www.ncbi.nlm.nih.gov/pubmed/32914017
http://dx.doi.org/10.1200/PO.18.00297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446396/
https://www.ncbi.nlm.nih.gov/pubmed/32914017
http://dx.doi.org/10.1200/PO.18.00297

Ejemplares similares